Evidence map›Paper›PMID 39135289›Full record

ArticleJournal of cosmetic dermatology2024

Development and optimization of a methimazole microemulsion for topical application: Formulation characteristics and transdermal permeation.

Anayatollah Salimi, Hadis Hoseinzadeh, Saeed Mohammad Soleymani

Abstract read
In one paragraph

Article in Journal of cosmetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anayatollah SalimiDepartment of Pharmaceutics, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID https://orcid.org/0000-0003-1505-7969
Hadis HoseinzadehNanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Saeed Mohammad SoleymaniDepartment of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-1462-3930

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethimazole, an oral antithyroid drug, has recently gained attention for its skin-brightening effects when applied topically to treat melasma. This study aims to develop, optimize, and characterize a methimazole microemulsion as a novel, safe approach for local melasma treatment. MATERIALS AND

methodsWe prepared microemulsion formulations containing 3% methimazole by combining appropriate amounts of surfactants (Tween 80 and Span 20), propylene glycol cosurfactant, and an oil phase (oleic acid-transcutol p at a 1:10 ratio). We then assessed droplet size, stability, viscosity, and skin permeation using rat skin models.

resultsThe microemulsions' droplet sizes ranged from 7.06 to 28.13 nm, with viscosities between 120 and 254 centipoises. Our analysis identified droplet size, viscosity, and membrane release as significant independent variables. We determined the permeability parameters of the optimal formulation through rat skin, including steady-state permeability rate (J

conclusionWe found that the microemulsions' characteristics, physicochemical properties, and in vitro release depended on the surfactant-to-cosurfactant ratio, water content, and oil content. We developed an optimal formulation with a high surfactant-to-cosurfactant ratio and low water and oil percentages. This formulation shows potential for commercialization and manufacturing of final products.

Indexed as

Administration, CutaneousEmulsionsMethimazoleSkin AbsorptionSurface-Active AgentsAnimalsAntithyroid AgentsDrug CompoundingEthylene GlycolsHexosesMaleOleic AcidParticle SizePermeabilityPolysorbatesPropylene GlycolAntithyroid AgentscarbitolEmulsionsEthylene GlycolsHexosesMethimazoleOleic AcidPolysorbatesPropylene Glycolsorbitan monooleateStearic AcidsSurface-Active Agentsmelasmamethimazolemicroemulsionoptimizationpermeability

Identifiers

PMID39135289
PMCPMC11626322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.